Imaavy Injection, Solution, Concentrate
FDA Recall NDC 57894-800
Latest: Class II · Status: Ongoing · Initiated Sep 23, 2026 · 1 enforcement report
Active & Historical Enforcement Reports
The FDA has identified 1 recorded enforcement report(s) associated with Imaavy (NDC 57894-800). A significant event, classified as Class II, was initiated on Sep 23, 2026 by Janssen Biotech, Inc.. The reported reason for this action was: "Presence of particulate matter."
This recall is currently ONGOING. Healthcare providers and patients are advised to check their inventory immediately against the affected codes provided below.
This recall is currently ONGOING. Healthcare providers and patients are advised to check their inventory immediately against the affected codes provided below.
Reported Recall Events
Class II Ongoing
Presence of particulate matter.
Sep 23, 2026
Oct 14, 2026
49 vials
Recall Profile & Regulatory Data
Event ID
99972
Classification
Class II
Enforcement Status
Ongoing
Recalling Firm
J&J INNOVATIVE MEDICINE
Voluntary / Mandated
Voluntary: Firm initiated
Distribution Pattern
OH
Product Description
IMAAVY (nipocalimab-aahu) Injection, 300 mg /1.62 mL (185 mg/mL) per single-dose vial, For Intravenous Infusion After Dilution, Rx only, Manufactured by: Janssen Biotech, Inc., Horsham, PA 19044. NDC: 57894-800-01
Batch or Lot Expiration Information
Lot# Lot JNYJ1208; Exp. 10/30/2027
Affected Packages Involved in this Recall
57894-801-01Imaavy
57894-800-01Imaavy
About FDA Recall Enforcement Reports
FDA recall data documents classified recall actions associated with a product. Most recalls are limited to specific lots, batches, or package configurations rather than every unit of a drug.
If a recall is listed for an NDC, review the affected lot information and package details carefully. Patients and healthcare professionals should confirm whether a specific product in hand matches the lot or package information before assuming it is affected.